Synthetic Biologics, Inc. (NYSE MKT: SYN), a biotechnology company developing novel anti-infective biologic and drug programs targeting specific pathogens that cause serious infections and diseases, announced today that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug designation to the Company’s proprietary SYN-005 monoclonal antibody (mAb) combination for the treatment of Pertussis, more commonly known as whooping cough. In the U.S., Orphan Drug Designation provides a variety of incentives, including seven years of market exclusivity, should SYN-005 receive FDA approval for the treatment of Pertussis.
{iframe}http://www.syntheticbiologics.com/2014-09-12-Synthetic-Biologics-Receives-Orphan-Drug-Designation-for-SYN-005-Treatment-for-Whooping-Cough-Pertussis?utm_source=BioMaryland+News+and+Events+-+10/14&utm_campaign=10-14&utm_medium=email{/iframe}